Sudeep Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sudeep Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹57 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹18 tied up three years earlier. More money tied up than 96% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹52 became extra profit. Higher than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹41Over the last 3 years, every ₹100 of reported profit came with ₹41 of operating cash.
Lower than 84% of Healthcare companies in India.
Self-Funding Ratio
0.8×Over the last 3 years its own operating cash paid for 78% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 71% of Healthcare companies in India.
Cash Locked Ratio
₹57For every ₹100 of sales, ₹57 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹18 tied up three years earlier.
More money tied up than 96% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹52Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹52 became extra profit.
Higher than 92% of Healthcare companies in India.
Asset Productivity Ratio
+50% / +180%In 3 years sales changed by +50% while total assets changed by +180%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.6×Debt due within a year is covered 0.6 times by its yearly operating cash.
Lower than 69% of Healthcare companies in India.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Higher than 57% of Healthcare companies in India.
Tangible Assets Ratio
94%Of every ₹100 the company owns, ₹94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 63% of Healthcare companies in India.
Tangible Net Worth Ratio
92%Of every ₹100 of net worth, ₹92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 59% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Sudeep Pharma Limited owes ₹0.24 for every ₹1 it owns. Net profit rose 25% in the year to Mar 2026, and grew 41% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
59.0Investors pay ₹59.0 for every ₹1 of Sudeep Pharma Limited's yearly profit, higher than 77% of Healthcare companies in India.
P/B ratio
12.30The share price is 12.30 times Sudeep Pharma Limited's book value per share, higher than 88% of Healthcare companies in India.
Market cap
₹10,866 CrThe total market value of all of Sudeep Pharma Limited's shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹883 CrWhat Sudeep Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹78.21Net worth divided by the number of shares. The share price of ₹962.00 is 12.3 times this, which is the P/B above.
Return on equity (ROE)
20.9%Sudeep Pharma Limited earned 20.9% on its shareholders' money over the last year, higher than 83% of Healthcare companies in India.
Owes vs Owns
0.24×Sudeep Pharma Limited owes ₹0.24 for every ₹1 it owns (low), lower than 76% of Healthcare companies in India.
Dividend yield
0.14%Sudeep Pharma Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Revenue growth
+28%Revenue rose 28% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit growth
+25%Net profit rose 25% in the year to Mar 2026, and grew 41% a year on average over 3 years.
Profit margin
27.1%Sudeep Pharma Limited keeps ₹27 of every ₹100 of revenue as net profit.
Cash quality
0.4×Cash from Sudeep Pharma Limited's business was 0.4× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
38.3×Sudeep Pharma Limited's operating profit covered its interest costs 38.3 times in the year to Mar 2026.
Cash vs debt
Net debtSudeep Pharma Limited had ₹36 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Sudeep Pharma Limited's P/E ratio?
Investors pay ₹59.0 for every ₹1 of Sudeep Pharma Limited's yearly profit, higher than 77% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sudeep Pharma Limited: ₹10,866 Cr ÷ ₹883 Cr (31 Mar 2026) = 12.3.
What is Sudeep Pharma Limited's return on equity?
Sudeep Pharma Limited earned 20.9% on its shareholders' money over the last year, higher than 83% of Healthcare companies in India.
How much does Sudeep Pharma Limited owe compared with what it owns?
Sudeep Pharma Limited owes ₹0.24 for every ₹1 it owns (low), lower than 76% of Healthcare companies in India.
Does Sudeep Pharma Limited pay a dividend?
Yes. Sudeep Pharma Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Is Sudeep Pharma Limited's revenue growing?
Revenue rose 28% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.